⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
accessnewswire.com
REGN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Regeneron Pharmaceuticals, Inc. (REGN) And Encourages Investors to Reach Out
accessnewswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
accessnewswire.com
REGN
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
globenewswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
prnewswire.com
REGN
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
globenewswire.com
REGN
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN
Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
globenewswire.com
REGN
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis
globenewswire.com
MRK
SNY
AZN
REGN
JNJ
CABA
Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight
prnewswire.com
NVO
BMY
JNJ
AMGN
REGN
SNY
PFE
AZN
LLY
NVS